Dr. Helmuth van Es joins BIMINI Biotech as Independent Supervisory Board Member

Leiden, 6 January 2026 – BIMINI Biotech is pleased to announce the appointment of Dr. Helmuth van Es as an Independent Supervisory Board Member.

Dr. van Es is a highly experienced biotech entrepreneur and life sciences executive, with more than 30 years of experience in drug discovery and development, company development, and strategic leadership. He began his career as a senior scientist at Crucell (formerly IntroGene) and was a co-founder of Galapagos, where he served as Head of Science at the Leiden site. Throughout his career, Dr. van Es has co-founded and held senior leadership and board positions in several biotechnology companies, including Citryll, Audion Therapeutics, Antabio, and Effecta Pharma. His experience spans multiple therapeutic areas, including autoimmune diseases, infectious diseases, oncology, and regenerative medicine, and he has been closely involved in advancing programs from early discovery through clinical development and financing.

Dr. van Es brings a wealth of experience that will be instrumental in supporting BIMINI’s mission to develop first-in-class therapeutics, strategic execution, and long-term value creation. Dr. van Es joins the Supervisory Board alongside Rob Mayfield, Vasily Kazey, and Rouslan Michtchenko, further strengthening BIMINI’s governance and strategic oversight as the company advances its pipeline.

Dr. Helmuth van Es: “I am thrilled to join the company’s Supervisory Board and work with the Board and Management Team to develop the company, progress BIMINI’s programs and get its drug candidates clinically tested. WASp biology is complex but has high potential for developing medicines for diseases with a true unmet medical need.”

BIMINI Biotech warmly welcomes Dr. van Es and looks forward to his contributions.